5G marketing is ubiquitous and the potential is huge. But when will consumers feel the impact? What's ahead and when with Jeff McElfresh, the CEO of AT&T Communications. From Investing in Tech: Tip of the 5G Iceberg.
5G marketing is ubiquitous and the potential is huge. But when will consumers feel the impact? What's ahead and when with Jeff McElfresh, the CEO of AT&T Communications. From Investing in Tech: Tip of the 5G Iceberg.
QuantumScape, a battery developer for electric vehicle use, began trading on the New York Stock Exchange today following a SPAC merger.
Expectations of good news on the near horizon are buoying markets right now. Over the past month, both the S&P 500 and the NASDAQ are up 11% to new record highs.Investors are excited at the prospect of a COVID vaccine coming before the winter is out. And the electoral results, that Democrat Joe Biden will ascend to the Presidency while the Republicans will emerge strengthened in Congress, promise the avoidance of extremes typical of divided government. In short, investors are looking forward to ‘return to normal’ environment over the next several months. And that has them seeking stocks that are primed for gains. Against this backdrop, Goldman Sachs analysts are pounding the table on three stocks in particular, noting that each could surge over 40% in the year ahead. After running both tickers through TipRanks’ database, we found out that the rest of the Street is also standing squarely in the bull camp.Codiack BioSciences (CDAK)As we have all learned from coronavirus pandemic, some new thing in medical science can make huge impact on our world. Codiack aims to turn that principle to good. This research-oriented pharmaceutical aims to turn exosome therapeutics into a whole new class of medicines. Exosomes are the degradation mechanism RNA, and can transfer genetic material around a body.And therein lies the potential. Codiack has developed a design platform for the engineering of exosome proteins capable of carrying and protecting drug molecules through cell walls. In effect, the proteins will mimic the pathways used by viruses – but are non-viral, and are designed to carry a ‘payload’ of therapeutic agents. If successful, exosome therapy offers doctors the ability to design a drug that will deliver specific agents to specific cells to fight specific disease.Codiack is involved in all aspects of exosome therapeutics, from design to manufacturing, and currently has an active pipeline of agents – seven, in all – in various stages of discovery, preclinical testing, and the beginnings of Phase 1 trials.In the biosciences, success or failure is all about that pipeline, and in its diverse, active pipeline of agents in a new sector of biotechnological pharmaceuticals, Codiack has a fine resource to attract investors. To get those investors, the company went public this past October, selling 5.5 million shares at an opening price of $14.10 per share.Among the healthcare name's fans is Goldman Sachs analyst Graig Suvannavejh. The analyst wrote, “Biopharma industry interest in exosomes has long been high, but engineering them for a specific function and manufacturing at scale have both proven challenging. Among a field of multiple competitors, CDAK has made the most significant progress on both fronts, and as such we view their technology platform as best-in-class.”"Given share underperformance (-37%) since the IPO, we find risk/reward highly compelling at current levels, and with key 2021 data sets to provide potential de-risking and positive share inflection," the analyst concluded.Suvannavejh rates CDAK a Buy, and his $29 price target shows the extent of his confidence – it implies a 222% upside for the coming year. (To watch Suvannavejh’s track record, click here)Overall, Codiack has a Strong Buy from the analyst consensus – 3 reviewers have put up Buy ratings in recent weeks. The stock is selling for $8.90, and its $24 average price target implies a 166% one-year upside potential. (See CDAK stock analysis on TipRanks)Arcutis Biotherapeutics (ARQT)Acrutis is a pioneering researcher in the treatment of dermatological disease. Arcutis is involved in discovering the next generation of dermatological treatments – an important niche, especially when one realizes that one common ailment, psoriasis, has not seen an FDA approval for a novel treatment in over two decades.The company is leveraging recent advances in immunology and inflammation to find new approaches to skin treatment. The goal is to make it easier for patients and doctors together to manage conditions like psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name just a few.The company's lead candidate, ARQ-151 (roflumilast cream), is about to enter a phase 3 trial for atopic dermatitis, and is in an advanced phase 3 stage in Plaque Psoriasis. Arcutis has recently issued an update on positive data from the Phase 2 trials of ARQ-151 in atopic dermatitis. The drug is a once-daily treatment, and has demonstrated significant patient relief from symptoms, especially itching and itching-related sleep problems. This is another stock in Suvannavejh’s coverage universe. The Goldman analyst is impressed by developments in the company’s pipeline work, noting: “ARQT provided an update on the outcome of its end-of-Phase 2 meetings with the FDA, following their Phase 2a trial of ARQ-151 in atopic dermatitis (AtD). Feedback from regulators was broadly encouraging, in particular, acknowledging the robust long-term safety data being generated by ARQT for ARQ-151 in plaque psoriasis…”Accordingly, Suvannavejh rates ARQT a Buy, and sets a $36 price target that indicates room for 40% upside growth in 2021. (To watch Suvannavejh’s track record, click here)Arcutis has 2 recent Buy reviews, making the consensus rating a Moderate Buy. The stock’s average price target is $37, suggesting a 44% upside from current levels. (See ARQT stock analysis on TipRanks)Oak Street Health (OSH)With the last stock, we move from medical research to medical care. Specifically, Oak Street Health is a primary care clinic operator, and part of the Medicare Network. The company has operations and clinics in Illinois, Indiana, Michigan, Pennsylvania, and Ohio, along with New York, North Carolina, Rhode Island, Tennessee, and Texas. It has been in operation for eight years, and went public this past summer, holding the IPO in August.In the third quarter, the company’s first as a publicly traded entity, OSH brought in $217.9 million in revenue. The revenue number was up 56% from the year-ago quarter. Earnings per share matched expectations, at 15 cents.The company’s expansion proceeds apace, and in October, Oak Street entered New York by opening, in Brooklyn, its 70th location. A planned expansion in Texas, involving a partnership with Walmart, is also proceeding as planned, and Oak Street has opened its first Walmart Community Clinic the Dallas-Fort Worth area city of Carrollton.Robert Jones, covering this stock for Goldman, set a $74 price target to back his Buy rating. At currently levels, this target implies an upside of ~58% in the next 12 months. (To watch Jones’ track record, click here)“Results suggest operations are still on track, with few incremental updates since the 2Q call, where management noted a resumption of center openings, (pivoted) marketing efforts, and in-person visits despite COVID. In 3Q, OSH opened 13 new centers and is on track for 73-75 by end of year… The company maintained that it is continuing to operate at a high level in places with elevated COVID case counts like Chicago and Detroit,” Jones noted.All in all, the Strong Buy analyst consensus rating OSH is based on 8 reviews, breaking down to 7 Buys and just a single Hold. The stock is selling for $46.94, and its $61.29 average price target suggests it has a ~31% upside for the coming year. (See OSH stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
“Investors have become uninterested in worrying about downside risks,” writes one Wall Street strategist.
You’ll have to pay more for Comcast’s services starting next year. The company will raise its prices for both cable TV and internet, and according to a price list posted on Reddit, they’ll be effective as soon as January 1st, 2021. According to the poster, the new prices are for the Chicago area, but Ars Technica has confirmed that price hikes are coming to all customers across the US.
John Buckingham of The Prudent Speculator investment newsletter provides a special screen of stocks for MarketWatch premium subscribers.
The feasibility of President-elect Joe Biden’s bold plan for sweeping tax increases on the wealthy has been vastly diminished in the absence of big Democratic wins in the U.S. House of Representatives and Senate. Biden’s focus on raising income taxes on the top 1% of earners, for instance, could appeal to some Republicans nodding toward a more populist agenda and get pushed through. “Since it wasn’t a blue wave, it’s much less likely we’ll see sweeping reform,” says Ali Hutchinson, managing director at Brown Brothers Harriman.
After what can only be described as a tumultuous year, with 2021 at the gate, both Wall Street and Main Street are exuding a sense of optimism.Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) have contributed toward the renewed sense of hope; Positive late stage data from the pharma companies’ respective Covid-19 vaccine programs has brought with it the very real prospect the pandemic could soon be over.However, looking beyond the near-term implications, Leerink analyst Mani Foroohar believes that among this select list of companies, one’s outlook is not all that rosy.The investment thesis for Moderna, says Foroohar, just doesn’t hold water.The analyst rates MRNA an Underperform (i.e. Sell) along with a $60 price target. Should Foroohar’s thesis play out, investors would see a 53% drop from current levels. (To watch Foroohar’s track record, click here)So, what’s behind the downbeat assessment?The analyst explained, “As we are in the midst of a global buildout of capacity analogous to a Manhattan project for vaccines, we see excess capacity, high competitive intensity, and limited pricing power as likely long-term structural features of vaccine end-markets, presenting secular challenges to a sub-scale player such as MRNA.”Foroohar’s assessment might seem to run counter to the positivity surrounding Moderna, especially following the release of excellent Phase 3 data for its Covid-19 vaccine candidate mRNA-1273 and its anticipated emergency use authorization (EUA).However, while Forhoohar actually increased his FY2021 revenue estimates for mRNA-1273 from $2.4 billion to $4.5 billion – roughly the same as consensus estimates - it is further down the line when “significant competition, and a likely eroding revaccination market over time” will negatively impact its commercial potential. Furthermore, amongst mRNA vaccine makers, the analyst expects Moderna to play second fiddle to Pfizer/BioNTech’s offering.Moreover, with shares already up by a mighty 550% year-to-date and looking beyond the Covid-19 vaccine opportunity, the biotech’s remaining options, according to Forhoohar, just don’t cut the mustard.“Elsewhere in the pipeline, we see little near-term news flow to drive share outperformance for a company of MRNA’s market cap,” the analyst said. “Consequently, we don’t see a clear and probable catalyst to reset shares higher, current valuation and expectations offer an unattractive risk/reward to investors.”Forhoohar, however, is currently amongst a minority on Wall Street. With 8 Buys, 4 Holds and 2 Sells, MRNA stock has a Moderate Buy consensus rating. Yet, considering the average price target stands at $108.62, the analysts anticipate ~15% downside over the coming months. (See MRNA stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Rhythm Pharmaceuticals gained Food and Drug Administration approval for an obesity drug for patients with rare genetic deficiencies, and RYTM stock rocketed to a two-month high.
If I figure in the private mortgage I wrote for my daughter—which I consider comparable to a bond investment—the mix is more like 67% stocks and 33% conservative investments. At age 57, this is an income stream I hope to outlive—but I could be wrong. At the top of my list is Social Security, which I plan to claim at age 70.
Ford has been among the worst-performing auto stocks during the past five years. Its new CEO could help fix the company and send its share higher.
Apple has been an American success story several times over with the Mac, iPod, iPhone and other inventions. But is Apple stock a buy now? Here's what its stock chart and earnings show.
The CEO and investors are clearly confident that the business will grow into its now more than $16 billion valuation.
Jeremy Siegel, the Wharton professor credited for calling Dow 20,000 in 2015, predicted that the market could be in for a solid gain in the coming year based on three factors.
Looking for an alternative to low-interest savings accounts or bonds? Check out these S&P; 500 stocks that pay an annual dividend yield of over 7%.
Citron Research editor and notorious short seller added another name to his holiday short list on Friday.In a tweet, Left said he has a short position in Palantir Technologies Inc (NYSE: PLTR) after the stock has more than tripled from its $10 direct listing price back on Sept. 30. Left is shorting Palantir and with a $20 price target by the end of the year, suggesting more than 50% downside from current levels."What a run the past month for all. But as traders looking for short exposure, $PLTR is no longer a stock but a full casino. Does not take a ball of crystal to know this will fall back to Arda," Left tweeted.Related Link: Citron Says It's 'Insulting' To Call Blink Charging An EV StockOther Short Bets On EV Stocks: His valuation-based short thesis for Palantir is similar to his short thesis for electric vehicle stock Nio Inc - ADR (NYSE: NIO) back on Nov. 13. In November 2018, Left compared Nio to Tesla Inc (NASDAQ: TSLA) when Nio was trading at around $7 per share, but he said this month that investors should take profits on the stock after it has gained nearly 2,300% in the past year."After a rocky road of trading, NIO has found itself in unchartered territory that can never be justified by its current standing in the China EV market or its near-term prospects," Left said of Nio.Left has also recently called Electrameccanica Vehicles Corp (NASDAQ: SOLO) "a complete joke" and EV charging station stock Blink Charging Co (NASDAQ: BLNK) a "total scheme."Benzinga's Take: Short sellers that have focused on fundamental valuation analysis have been getting killed for years now, especially when it comes to betting against EV stocks. The fact that Left specifically mentioned his $20 price target for Palantir is for "2020" suggests it may simply be a short-term bet on a correction rather than a longer-term commentary on the stock.See more from Benzinga * Click here for options trades from Benzinga * Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
A“double up” strategy lets investors keep their stock, avoiding realizing losses, and position for a rebound at more favorable prices.
2020 has been a year like no other, with earth shattering events hogging the headlines. But the year has also provided many interesting sub-plots. One of which has been the rise of Zoom (ZM). The video conferencing platform has become a household name in the year of Covid-19, but for investors, ZM stock has also been the gift that keeps on giving. Shares are up by a whopping 594% year-to-dateAfter crushing the estimates in previous earnings reports, can the high-flying tech company repeat the feat once again? Ahead of next week’s earnings report, RBC analyst Alex Zukin expects Zoom to keep on outperforming.“As we enter the fiscal 3Q report, we continue to see material upside to guidance/consensus expectations both in the quarter and for the year,” the 5-star analyst said. “With investor debate starting to center on the company’s ability to comp the tremendous growth achieved in FY21, our upside scenario still points to ~60% revenue growth in FY22.”Zukin, who's ranked at 5 out of over 7,100 analysts on TipRanks, rates ZM an Outperform (i.e. Buy) along with a $600 price target. The implication for investors? Upside of another ~27%. (To watch Zukin’s track record, click here)Zukin remains confident despite data showing a slowdown in app downloads since April’s peak. However, download levels still remain “significantly above pre-COVID levels.” Bolstering the bullish case, MAU (monthly active users) trends are “much stronger and have actually eclipsed April highs.” Zukin puts the uptick down to back to school activity. In each successive month of the quarter, MAUs have increased; up from 145 million in August to 210 million in September and peaking at 222 million in October.“We note that if trends similar to F2Q—where ZM generated incremental revenue of $1.62 per download—hold, the company would post total revenue of $909M (+446% Y/Y) in F3Q,” Zukin said.That figure is actually higher than Zukin’s projection. The analyst expects Zoom to post revenue between $813–900 million. Still, this forecast is 17–30% ahead of the Street’s estimate of $693 million.While Zukin’s assessment is conclusively positive, the rest of the Street’s take is a mixed bag; Based on 11 Buys, 12 Holds, and 1 Sell, Zoom has a Moderate Buy consensus rating. Overall, analysts expect the stock to stay range-bound for the foreseeable future, as the $477.67 average price target indicates. (See Zoom stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Nio Inc - ADR (NYSE: NIO) has remained a favorite among Wall Street firms, with most remaining bullish on the Chinese electric vehicle maker. Following investor calls with the automaker's management, an analyst at BofA Securities shared key takeaways Friday. The Nio Analyst: Analyst Ming Hsun Lee maintained a Buy rating on Nio with a $54.70 price target. The Nio Thesis: BofA's positive view on Nio is predicated on its long-term share gain potential in the premium EV market and improving profitability along with "rising scale," Hsun Lee said in a Friday note.Nio is planning to introduce its first sedan model and reveal more details on NP2 at its Nio Day scheduled for January 2021, the analyst said. The NP2 is Nio's next vehicle platform that's expected to boast advanced autonomous driving features, he said. The company is modeling vehicle gross margin of about 15%-20% over the long term, Hsun Lee said.The company is open to adopting Lidar in the future, the analyst said. Related Link: EV Stocks Continue Rally As Short Sellers Question Valuations Nio plans to expand point of sales, including Nio Houses and Nio Spaces, from 187 to 200 by the end of 2020, and add another 100 in 2021, he said. The EV maker is planning to start building its second-generation battery swap stations in the second quarter of 2021, with 300 stations likely to be built in 2021, Hsun Lee said. The rapidly expanding battery swap network, according to the analyst, will further improve the Nio user experience.Nio expressed confidence in defending its market share against traditional OEMs, which are planning a foray into the high-end EV market, as the company believes it takes a long time to build brand equity and consumer perception, according to BofA. NIO Price Action: At last check, Nio shares were advancing 0.64% to $54.04. Related Link: High-Flying Chinese EV Stocks Hit Roadblock Amid Domestic Regulatory Scrutiny A Nio ES6 SUV. Courtesy photo. Latest Ratings for NIO DateFirmActionFromTo Nov 2020Deutsche BankMaintainsBuy Nov 2020B of A SecuritiesMaintainsBuy Oct 2020JP MorganUpgradesNeutralOverweight View More Analyst Ratings for NIO View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * High-Flying Chinese EV Stocks Hit Roadblock Amid Domestic Regulatory Scrutiny * EV Stocks Continue Rally As Short Sellers Question Valuations(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Elon Musk’s electric-vehicle maker continues its amazing rise. Tesla’s value is now so high that car-making profits alone, even looking out a decade and assuming massive market-share gains, might not be enough.
Hopes for improved oil and gas demand in the new year won't be enough to get Exxon Mobil to fund its dividend solely from cash flow, and the energy giant faces 'unenviable' choices, Raymond James analysts say.